Understanding Gastrointestinal Oxalate Metabolism in Kidney Stone Disease: A Stable Isotope Study
Lisa J. Deesker(Emma Kinderziekenhuis), Jaap W. Groothoff(University of Amsterdam), Michiel J.S. Oosterveld(Emma Kinderziekenhuis), Tim de Meij(Emma Kinderziekenhuis), Dewi van Harskamp(Emma Kinderziekenhuis), Sander F. Garrelfs(Emma Kinderziekenhuis)
Cited by 0
Related Papers
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
|Nephrology Dialysis Transplantation|2012|335
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope
|Nature Reviews Nephrology|2023|154
Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria
|Nephrology Dialysis Transplantation|2011|144
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up
|Kidney International|2019|103